Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | SCN1A | P35498 | 3/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975221 | 0.93 | SCN8A (0.45) | LMNAMAPK1RAB9AGRIN1GRIN2B | |
| SCHEMBL973549 | 0.87 | SCN8A (0.40) | LMNAMAPK1RAB9AGRM5SCN1A | |
| SCHEMBL3322466 | 0.79 | HTT (0.61) | LMNAMAPK1RAB9ASCN1ASCN8A | |
| SCHEMBL4700278 | 0.77 | GRM5 (0.45) | RAB9AGRIN2BGRM5SMN1; SMN2 | |
| SCHEMBL4701149 | 0.75 | GRIN2B (0.41) | LMNAMAPK1RAB9AGRIN1GRIN2B | |
| SCHEMBL3144817 | 0.74 | GRM5 (0.52) | LMNAMAPK1RAB9AGRM5 | |
| SCHEMBL973961 | 0.73 | GRIN2B (0.42) | RAB9AGRIN2BGRM5SCN1ASCN8A | |
| Hydrochloric Acid SCHEMBL3151562 | 0.73 | GRM5 (0.51) | LMNAMAPK1RAB9AGRM5 | |
| SCHEMBL2852667 | 0.71 | SIGMAR1 (0.44) | GRIN1GRIN2BGRM5SCN1ASCN8A | |
| SCHEMBL972113 | 0.71 | DRD2 (0.53) | LMNAMAPK1RAB9AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318774-B2 | N-(3-((thiazol-2-yl)amino)propyl)-3-phenylpropiolamide, 4-(thiazol-2-yl-amino)-1-(3-phenyl-propiolyl)piperidine, for example; for preventing or treating a disorder or disease that is mediated at least in part by mGluR26 receptors, such as pain, migraines, depression, neurodegenerative diseases | GRUENENTHAL GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| EP-1968958-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079961-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-8318774-B2 | N-(3-((thiazol-2-yl)amino)propyl)-3-phenylpropiolamide, 4-(thiazol-2-yl-amino)-1-(3-phenyl-propiolyl)piperidine, for example; for preventing or treating a disorder or disease that is mediated at least in part by mGluR26 receptors, such as pain, migraines, depression, neurodegenerative diseases | GRUENENTHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1968958-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079961-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269295-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, ABCB1, FDPS | LMNA 3872/4885MAPK1 3957/4885RAB9A 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.